Find trials
Search tips

A Study to Detect Actionable or Predictive Tumor DNA Mutations in Peripheral Blood (Liquid Biopsy) from Patients with Cholangiocarcinoma (CCA)

Overview

About this study

The purpose of this study is to investigate the feasibility of isolating circulating tumor cells (CTCs) and cfDNA from patients with CCA for molecular characterization and compare the mutation results between peripheral blood and tumor tissue.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • Adult, age ≥ 18 years old.
  • Patients with active disease of intrahepatic, perihilar, distal CCA with histologic confirmation.
  • Patients whose clinical provider orders cancer tissue mutation profiling test for clinical care.

Exclusion Criteria: 

  • Females who are pregnant or attempting to become pregnant.
  • Patient with significant anemia (Hemoglobin <7g/dL).

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Jacksonville, Fla.

Mayo Clinic principal investigator

Kabir Mody, M.D.

Closed for enrollment

Rochester, Minn.

Mayo Clinic principal investigator

Lewis Roberts, M.B., Ch.B., Ph.D.

Closed for enrollment

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Mitesh Borad, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20452038

Mayo Clinic Footer